Surmodics, Inc. (SRDX) director Jose Bedoya, Sold $551,589 in Stock; Ciena Has 0.94 Sentiment

May 24, 2018 - By Ash

Surmodics, Inc. (NASDAQ:SRDX) Logo

Ciena Corp (CIEN) investors sentiment decreased to 0.94 in Q4 2017. It’s down -0.06, from 1 in 2017Q3. The ratio dived, as 120 hedge funds started new or increased holdings, while 127 sold and reduced holdings in Ciena Corp. The hedge funds in our database now hold: 142.49 million shares, down from 148.04 million shares in 2017Q3. Also, the number of hedge funds holding Ciena Corp in top ten holdings was flat from 1 to 1 for the same number . Sold All: 47 Reduced: 80 Increased: 76 New Position: 44.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company has market cap of $3.52 billion. The companyÂ’s Networking Platforms segment offers hardware networking solutions optimized for the convergence of coherent optical transport, optical transport network switching, and packet switching. It has a 5.22 P/E ratio. The Company’s products include 6500 Packet-Optical Platform and the 5430 Reconfigurable Switching System, Waveserver stackable interconnect system, CoreDirector Multiservice Optical Switches, and OTN configuration for the 5410 Reconfigurable Switching System, as well as Z-Series Packet-Optical Platform; 3000 family of service delivery switches and service aggregation switches, and the 5000 family of service aggregation switches, as well as 8700 Packetwave Platform and the Ethernet packet configuration for the 5410 Service Aggregation Switch; and 4200 Advanced Services Platform, Corestream 5100/5200 Advanced Services Platform, Common Photonic Layer, and 6100 Multiservice Optical Platform.

Analysts await Ciena Corporation (NYSE:CIEN) to report earnings on May, 31 before the open. They expect $0.23 earnings per share, down 39.47% or $0.15 from last year’s $0.38 per share. CIEN’s profit will be $33.02M for 26.66 P/E if the $0.23 EPS becomes a reality. After $0.07 actual earnings per share reported by Ciena Corporation for the previous quarter, Wall Street now forecasts 228.57% EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 57 selling transactions for $4.35 million activity.

Another recent and important Ciena Corporation (NYSE:CIEN) news was published by Benzinga.com which published an article titled: “Benzinga’s Top Upgrades, Downgrades For May 24, 2018” on May 24, 2018.

The stock increased 0.06% or $0.015 during the last trading session, reaching $24.525. About 703,964 shares traded. Ciena Corporation (CIEN) has risen 9.21% since May 24, 2017 and is uptrending. It has underperformed by 2.34% the S&P500.

Altalis Capital Management Llc holds 3.27% of its portfolio in Ciena Corporation for 160,215 shares. Managed Asset Portfolios Llc owns 376,823 shares or 2.5% of their US portfolio. Moreover, Broadview Advisors Llc has 2.06% invested in the company for 690,450 shares. The Wyoming-based Southport Management L.L.C. has invested 1.54% in the stock. Swarthmore Group Inc, a Pennsylvania-based fund reported 257,825 shares.

Ratings analysis reveals 50% of Ciena’s analysts are positive. Out of 8 Wall Street analysts rating Ciena, 4 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $18.5 while the high is $30.0. The stock’s average target of $25.30 is 3.16% above today’s ($24.525) share price. CIEN was included in 8 notes of analysts from August 29, 2016. Drexel Hamilton downgraded Ciena Corporation (NYSE:CIEN) on Friday, September 2 to “Hold” rating. The rating was initiated by Stifel Nicolaus on Friday, September 30 with “Hold”. As per Tuesday, December 20, the company rating was initiated by Piper Jaffray. The rating was maintained by M Partners on Friday, December 9 with “Buy”. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, September 2. Deutsche Bank maintained the shares of CIEN in report on Monday, August 29 with “Hold” rating. The firm has “Buy” rating by UBS given on Friday, January 13. The firm earned “Buy” rating on Friday, September 2 by Dougherty & Company.

Among 5 analysts covering SurModics (NASDAQ:SRDX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. SurModics has $5500 highest and $29 lowest target. $41.88’s average target is -14.53% below currents $49 stock price. SurModics had 9 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Sidoti given on Friday, October 7. The rating was maintained by Needham with “Buy” on Wednesday, May 16. The stock of Surmodics, Inc. (NASDAQ:SRDX) has “Mkt Perform” rating given on Monday, November 21 by Barrington Research. The stock has “Outperform” rating by Barrington Research on Thursday, August 6. As per Wednesday, May 2, the company rating was maintained by Needham. Barrington Research upgraded the stock to “Outperform” rating in Wednesday, February 28 report.

Analysts await Surmodics, Inc. (NASDAQ:SRDX) to report earnings on August, 2. They expect $-0.08 EPS, down 188.89% or $0.17 from last year’s $0.09 per share. After $0.07 actual EPS reported by Surmodics, Inc. for the previous quarter, Wall Street now forecasts -214.29% negative EPS growth.

Since December 11, 2017, it had 0 insider buys, and 2 insider sales for $63,711 activity. Stich Joseph J. sold $30,183 worth of stock.

More notable recent Surmodics, Inc. (NASDAQ:SRDX) news were published by: Seekingalpha.com which released: “Surmodics’ (SRDX) CEO Gary Maharaj on Q2 2018 Results – Earnings Call Transcript” on May 02, 2018, also Streetinsider.com with their article: “SurModics (SRDX) PT Raised to $55 at Needham & Company” published on May 16, 2018, Nasdaq.com published: “Biothera Pharmaceuticals Appoints Andrew DC LaFrence Chief Financial Officer” on May 16, 2018. More interesting news about Surmodics, Inc. (NASDAQ:SRDX) were released by: Bizjournals.com and their article: “SurModics CFO LaFrence leaves for pharma company” published on May 16, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” with publication date: May 17, 2018.

Jose Bedoya, an insider of Surmodics Inc, currently director not a long ago disclosed a deal with the D.C. based-SEC. As reported in the legal form, Jose Bedoya sold 11,450 shares of the public firm, priced at $48.2 per share. $551,589 U.S. Dollars was the deal’s value. The SEC document’s date was 23-05-2018. Currently, Mr. Jose, possess 19,439 shares, which accounts for 0.15% of the Company’s market cap.

The stock decreased 1.11% or $0.55 during the last trading session, reaching $49. About 7,391 shares traded. Surmodics, Inc. (NASDAQ:SRDX) has risen 61.37% since May 24, 2017 and is uptrending. It has outperformed by 49.82% the S&P500.

Investors sentiment decreased to 0.69 in Q4 2017. Its down 0.25, from 0.94 in 2017Q3. It fall, as 11 investors sold Surmodics, Inc. shares while 44 reduced holdings. 12 funds opened positions while 26 raised stakes. 11.07 million shares or 0.98% less from 11.18 million shares in 2017Q3 were reported. 276,792 are held by Teton Advsr Inc. California-based Schwab Charles Mgmt Inc has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Arizona State Retirement System reported 0.01% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX). 2,173 were accumulated by Barclays Public Limited Company. Segall Bryant And Hamill Limited Liability Company holds 141,473 shares. National Bank & Trust Of Montreal Can reported 0% stake. Credit Suisse Ag has 22,628 shares. Ameritas Prns Inc invested in 1,145 shares. Parallax Volatility Advisers Limited Partnership holds 2,016 shares or 0% of its portfolio. Teachers Retirement Of The State Of Kentucky holds 0% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX) for 1,798 shares. Rice Hall James And Assocs Lc reported 104,386 shares stake. Swiss Bancorporation stated it has 22,800 shares or 0% of all its holdings. Acadian Asset Mgmt owns 0.02% invested in Surmodics, Inc. (NASDAQ:SRDX) for 127,544 shares. New York-based Ny State Common Retirement Fund has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Wells Fargo & Mn has 28,209 shares.

Surmodics, Inc., together with its subsidiaries, provides surface modification and in vitro diagnostic technologies to the healthcare industry worldwide. The company has market cap of $649.64 million. It operates through two divisions, Medical Device and In Vitro Diagnostics. It has a 24500 P/E ratio. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: